1 BTC
=
- USD
Supernus Pharmaceuticals, Inc.
As of May 30, 2026 at 24:05 UTC
Chart
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Market Statistics
Trading Metrics
How to Buy SUPN
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy SUPN
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesSupernus Pharmaceuticals announced that President and CEO Jack A. Khattar will participate in a fireside chat at the Bank of America 2026 Health Care Conference on May 12, 2026. The company reported strong Q1 2026 financial results with total revenues of $207.7 million, representing a 39% increase year-over-year, with combined revenues from four growth products reaching $149.1 million.
Supernus Pharmaceuticals announced that management will participate in three major healthcare investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference (March 2), Jefferies Biotech on the Beach Summit (March 10), and Barclays 28th Annual Global Healthcare Conference (March 11). Live webcasts will be available for select presentations.
Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system diseases, will host a conference call on February 25, 2025, to discuss its fourth quarter and full-year 2024 financial results.